

1 Hyperinflammatory ARDS is characterized by interferon-stimulated gene expression, T-cell
2 activation, and an altered metatranscriptome in tracheal aspirates
3

4 **Authors:** Aartik Sarma¹, Stephanie A. Christenson¹, Beth Shoshana Zha¹, Angela Oliveira
5 Pisco², Lucile P.A. Neyton¹, Eran Mick^{2,3}, Pratik Sinha⁴, Jennifer G. Wilson⁵, Farzad Moazed¹,
6 Aleksandra Leligdowicz^{6,7}, Manoj V. Maddali⁸, Emily R. Siegel⁹, Zoe Lyon⁹, Hanjing Zhou¹,
7 Alejandra Jauregui¹, Rajani Ghale¹, Saharai Caldera², Paula Hayakawa Serpa^{2,3}, Thomas
8 Deiss¹, Christina Love², Ashley Byrne², Katrina L. Kalantar², Joseph L. DeRisi², David J.
9 Erle^{6,10,11,12}, Matthew F. Krummel^{11,13}, Kirsten N. Kangelaris¹⁴, Carolyn M. Hendrickson¹⁵,
10 Prescott G. Woodruff^{1,6}, Michael A. Matthay^{1,6,16}, COMET Consortium, Charles R. Langelier^{2,3},
11 Carolyn S. Calfee^{1,6,16}

- 12 1. Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of
13 Medicine, University of California San Francisco, CA
- 14 2. Chan Zuckerberg Biohub, San Francisco, CA
- 15 3. Division of Infectious Diseases, Department of Medicine, University of California San
16 Francisco, CA
- 17 4. Department of Anesthesia, Washington University in St Louis
- 18 5. Department of Emergency Medicine, Stanford University School of Medicine, Stanford
19 University, Stanford, CA
- 20 6. Cardiovascular Research Institute, University of California San Francisco, CA
- 21 7. Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto,
22 Ontario, Canada
- 23 8. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine,
24 Stanford University, Stanford, CA
- 25 9. School of Medicine, University of California San Francisco, CA
- 26 10. Lung Biology Center, University of California San Francisco, CA
- 27 11. Bakar ImmunoX Initiative, University of California San Francisco, CA
- 28 12. UCSF CoLabs, University of California San Francisco, CA
- 29 13. Department of Pathology, University of California San Francisco, CA
- 30 14. Division of Hospital Medicine, University of California San Francisco, CA
- 31 15. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Zuckerberg
32 San Francisco General Hospital and Trauma Center, University of California San
33 Francisco
- 34 16. Department of Anesthesia, University of California San Francisco, CA

35
36 **Funding:** F32HL151117 (AS), R35HL140026 (CSC), 2R24AA019661-06A1 (CSC), NIH/NHLBI
37 K23HL138461-01A1 (CRL), U19 AI1077439 (DJE, CSC), UCSF ImmunoX CoLabs, Chan
38 Zuckerberg Foundation 2019-202665, Genentech TSK-020586
39

40 **Abstract:** Two molecular phenotypes of the acute respiratory distress syndrome (ARDS) with
41 substantially different clinical trajectories have been identified. Classification as
42 “hyperinflammatory” or “hypoinflammatory” depends on plasma biomarker profiling. Differences
43 in the biology underlying these phenotypes at the site of injury, the lung, are unknown. We
44 analyze tracheal aspirate (TA) transcriptomes from 46 mechanically ventilated subjects to
45 assess differences in lung inflammation and repair between ARDS phenotypes. We then
46 integrate these results with metatranscriptomic sequencing, single-cell RNA sequencing, and
47 plasma proteomics to identify distinct features of each ARDS phenotype. We also compare

48 phenotype-specific differences in gene expression to experimental models of acute lung injury
49 and use an *in silico* analysis to identify candidate treatments for each phenotype. We find that
50 hyperinflammatory ARDS is associated with increased integrated stress response and interferon
51 gamma signaling, distinct immune cell polarization, and differences in microbial community
52 composition in TA. These findings demonstrate that each phenotype has distinct respiratory
53 tract biology that may be relevant to developing effective therapies for ARDS.

54

55 **Word count:** 3,994

56

57 **COMET Consortium:**

58 K. Mark Ansel^{17,18}, Yumiko Abe-Jones¹⁴, Saurabh Asthana^{11,13}, Alexander Beagle¹⁹, Sharvari
59 Bhide¹⁵, Cathy Cai²⁰, Sidney A. Carrillo¹, Suzanna Chak¹, Vincent Chan^{11,13,18}, Nayvin
60 Chew^{11,12,13,21}, Zachary Collins^{11,13}, Alexis Combes^{11,12,13,21}, Tristan Courau^{11,12,13,21}, Spyros
61 Darmanis²², Catherine DeVoe³, Gabriela K. Fragiadakis^{11,12,23}, Kamir Hiam^{2,18,20,24,25}, Kenneth
62 Hu^{11,13,21}, Billy Huang²⁶, Norman Jones²⁷, Nitasha Kumar²⁷, Divya Kushnoor^{11,12,13,21}, Tasha
63 Lea¹³, Deanna Lee^{6,15}, David Lee^{11,23,28}, Yale Liu¹⁹, Salman Mahboob²⁶, Jeff Milush²⁷, Priscila
64 Muñoz-Sandoval^{17,18}, Viet Nguyen^{6,15}, Randy Parada²⁶, Ravi Patel^{11,12}, Maira Phelps², Logan
65 Pierce¹⁴, Priya Prasad¹⁴, Arjun Rao^{11,13}, Sadeed Rashid²⁰, Gabriella Reeder^{11,12,29}, Nicklaus
66 Rodriguez²⁰, Bushra Samad^{11,13}, Cole Shaw^{11,12}, Alan Shen^{11,12,13,21}, Austin Sigman¹, Matthew
67 Spitzer^{2,18,20,24,25}, Yang Sun²³, Sara Sunshine³⁰, Kevin Tang²⁰, Luz Torres Altamirano²⁰,
68 Alexandra Tsitsiklis³, Jessica Tsui^{11,12,13,21}, Alyssa Ward²³, Andrew Willmore¹, Michael Wilson³¹,
69 Juliane Winkler²⁰, Kristine Wong²⁰, Jimmie Ye^{2,23,25,28,32,33}, Michelle Yu¹, Wandu Zhu^{17,18}

- 70 17. Sandler Asthma Basic Research Center, University of California San Francisco, CA
71 18. Department of Microbiology and Immunology, University of California San Francisco, CA
72 19. Department of Medicine, University of California San Francisco, CA
73 20. Helen Diller Family Comprehensive Cancer Center, University of California San
74 Francisco, CA
75 21. Department of Anatomy, University of California San Francisco, CA
76 22. Microchemistry, Proteomics and Lipidomics Department, Genentech Inc, 1 DNA Way,
77 South San Francisco, CA, 94080
78 23. Division of Rheumatology, Department of Medicine, University of California San
79 Francisco, CA
80 24. Department of Otolaryngology, University of California San Francisco, CA
81 25. Parker Institute for Cancer Immunotherapy, San Francisco, CA
82 26. Department of Orofacial Sciences, School of Dentistry, University of California San
83 Francisco, CA
84 27. Core Immunology Laboratory Division of Experimental Medicine, University of California
85 San Francisco, CA
86 28. Institute for Human Genetics, University of California San Francisco, CA
87 29. Biomedical Sciences Graduate Program, University of California San Francisco, CA
88 30. Department of Biochemistry and Biophysics, University of California San Francisco, CA
89 31. Weill Institute for Neurosciences, Department of Neurology, University of California San
90 Francisco
91 32. Department of Epidemiology and Biostatistics, University of California San Francisco,
92 CA
93 33. Institute of Computational Health Sciences, University of California San Francisco, CA
94

95 Introduction

96 The acute respiratory distress syndrome (ARDS) is a clinical condition characterized by
97 noncardiogenic pulmonary edema and hypoxemia within one week of a physiologic insult¹. This
98 broad clinical definition encompasses a heterogeneous population of critically ill patients,
99 including those with direct pulmonary injury from pneumonia or aspiration and those with
100 indirect pulmonary injury caused by dysregulated systemic inflammation from sepsis,
101 pancreatitis, or trauma. The global incidence of ARDS has surged during the COVID-19
102 pandemic, increasing the importance of finding effective treatments. While some pharmacologic
103 treatments have decreased mortality in mechanically ventilated patients with COVID-19^{2,3}, no
104 drug has consistently reduced mortality in more typical heterogeneous cohorts of patients with
105 ARDS. There is a growing recognition that biological heterogeneity within the syndrome is a
106 significant barrier to identifying effective treatments⁴.

107 Two clinically distinct molecular phenotypes of ARDS (termed “hyperinflammatory” and
108 “hypoinflammatory”) have been identified using latent class analysis of clinical and plasma
109 biomarker data in five clinical trial cohorts and three observational studies^{1,5-11}. The
110 hyperinflammatory phenotype is characterized by elevated plasma inflammatory cytokines (IL-8,
111 IL-6, TNF α), lower plasma Protein C and bicarbonate, and higher 90-day mortality compared
112 to the hypoinflammatory phenotype. Differences between phenotypes are not primarily
113 explained by the physiologic insult that caused ARDS (e.g. sepsis, pneumonia, aspiration of
114 gastric contents). Importantly, significant differences in treatment response to simvastatin,
115 ventilator settings, and fluid management have been observed across molecular phenotypes in
116 retrospective analyses of three ARDS clinical trials⁵⁻⁷; further, in patients with COVID-19-related
117 ARDS, hyperinflammatory patients may preferentially respond to corticosteroid treatment^{12,13}.
118 These results suggest that understanding and targeting the heterogeneous biology underlying
119 ARDS molecular phenotypes is essential to identifying effective new treatments for ARDS.
120 Prospective studies designed to identify these phenotypes using parsimonious models are
121 laying the groundwork for precision clinical trials^{4,14}.

122 Despite this exciting progress, a critical barrier to developing new therapies for ARDS is
123 our superficial understanding of the biological pathways characterizing each phenotype. This
124 knowledge gap was recently cited by an NHLBI workshop on precision medicine in ARDS as a
125 top research priority for the field⁴. To date, analyses of the biological differences between these
126 phenotypes have been limited to circulating biomarkers in plasma or blood, largely due to the
127 relative ease of sampling. Understanding the biological differences between ARDS phenotypes
128 in the lung will be critical to development of informative pre-clinical models of disease and

129 targeted treatments for ARDS. Here, we employ a systems biology approach incorporating bulk
130 and single-cell RNA-sequencing, metagenomics, and proteomics to understand differences in
131 lung immunology, microbiology, and systemic inflammatory responses between ARDS
132 phenotypes.

133

134 **Results**

135 **Patient enrollment and ARDS phenotype assignment**

136 To determine if previously identified ARDS phenotypes are associated with differences
137 in pulmonary biology, we first studied tracheal aspirates (TA) collected from the Acute Lung
138 Injury in Critical Illness study, a prospective, observational cohort of mechanically ventilated
139 patients admitted to the ICU at the University of California San Francisco Medical Center
140 (UCSFMC). Patients were enrolled in this cohort from July 2013 until March 2020, when
141 enrollment was paused due to the COVID-19 pandemic. 77 out of 323 participants had ARDS in
142 this cohort (Supplementary Figure 1). TA host sequencing was available for 41 of the ARDS
143 participants. In addition, we had TA sequencing from five participants who were intubated for
144 neurologic injury, had no evidence of pulmonary disease on chest x-ray (CXR), and were not
145 immunosuppressed. We used a previously validated three-variable classifier model to determine
146 ARDS molecular phenotype based on plasma IL-8, bicarbonate, and Protein C levels¹⁴. When
147 plasma biomarkers were unavailable from the day of TA collection (n=5), we used a recently
148 described and validated machine learning model to assign phenotype^{11,15}. 10 out of 41 ARDS
149 subjects (24%) had hyperinflammatory ARDS, which is consistent with the proportion of
150 hyperinflammatory subjects observed in previous studies⁵⁻⁹. There were four extrapulmonary
151 fungal infections (two *C. albicans*, one *C. glabrata*, and one *H. capsulatum*) in the
152 hyperinflammatory phenotype vs. zero in the hypoinflammatory phenotype ($p < 0.01$, Table 1).
153 There were no significant differences in patient age, sex, BMI, immunosuppression, or ARDS
154 risk factors between the groups.

155

156 **TA RNASeq identifies increased pro-inflammatory cytokine signaling and increased 157 stress response in hyperinflammatory ARDS**

158 We sequenced TA using established methods¹⁶ and used *DESeq2*¹⁷ and *apegI*¹⁸ to
159 compare TA gene expression between ARDS molecular phenotypes. 1,334 genes (7% of all
160 protein-coding genes) were differentially expressed between ARDS phenotypes at a false
161 detection rate (FDR) < 0.1 and absolute empirical Bayesian posterior \log_2 -fold change > 0.5
162 (Supplementary Figure 2A, Supplementary Data 1A).

163 We next used Ingenuity Pathway Analysis (IPA)¹⁹ Upstream Regulator analysis to
164 analyze differentially expressed genes. This analysis predicts whether measured gene
165 expression is consistent with activation or inhibition of upstream regulators of gene expression,
166 which include cytokines, receptors, transcription factors, enzymes, endogenous chemicals, and
167 drugs. IPA predicted increased activation of several cytokines and other upstream regulators of
168 differentially expressed genes in hyperinflammatory ARDS (Figure 1.A.i, Supplementary Data
169 2A). Predicted upstream regulators included several pro-inflammatory cytokines that were
170 previously found to be elevated in plasma of patients with hyperinflammatory ARDS, including
171 IL1B, IL6, and TNF. In addition, IPA identified activation of several cytokines that were not
172 previously associated with hyperinflammatory ARDS, including several interferons; IL2 and
173 IL15, which stimulate cytotoxic T cell and NK cell responses²⁰; and the chemokine ligand
174 CCL2/MCP-1. In addition, upstream regulator analysis predicted increased activation of the
175 integrated stress response (XBP1, NFE2L2), T cell activation (CD3, CD28), stimulation of Toll-
176 like receptors (TLR2, TLR3, TLR4, TLR7, TLR9), a metabolic shift to glycolysis (MLXILP), and
177 increased cellular differentiation (MYC, NONO) in hyperinflammatory ARDS (Figure 1.A.ii-iv,
178 Supplementary Data 2A). Because there was a significant difference in fungal infections
179 between phenotypes, we performed a sensitivity analysis adjusting for systemic fungal
180 infections. 997 genes were differentially expressed between phenotypes (711 genes overlapped
181 with the unadjusted analysis), and pathway analysis identified similar upstream regulators of
182 gene expression (Supplementary Figure 2, Supplementary Data 1B, Supplementary Data 2B).
183 Together, these analyses identify several novel pathways that are differentially regulated
184 between ARDS molecular phenotypes and support the hypothesis that previously described
185 differences in systemic inflammation are associated with marked differences in respiratory tract
186 biology

187 To further understand how pathways in each phenotype were dysregulated compared to
188 mechanically ventilated lungs, we next performed differential expression and pathway analyses
189 comparing each phenotype to five mechanically ventilated control samples (Figure 1B and 1C,
190 Supplementary Data 1C and 1D). 2,989 genes (15% of protein-coding genes) were differentially
191 expressed between hyperinflammatory ARDS participants and controls, while 2,132 genes
192 (11% of all protein-coding genes) were differentially expressed between hypoinflammatory
193 ARDS and controls. Notably, this analysis identified several cytokines that were activated in
194 both hyperinflammatory ARDS and hypoinflammatory ARDS compared to controls, including
195 IL1B, TNF, and IFNG. While this analysis identified some similarities between phenotypes, we
196 also identified several upstream regulators that were only significantly upregulated in

197 hyperinflammatory ARDS (Supplementary Data 2C and 2D), including IL-17C, a member of the
198 IL-17 family secreted by airway epithelial cells²¹; several Type I/Type III interferons; FAS, which
199 stimulates apoptosis²²; TICAM/MyD88 signaling, which are downstream effectors of Toll-like
200 receptors^{23,24}; and the T-cell receptor, suggesting these pathways play a role in the distinct
201 biology of hyperinflammatory ARDS.

202

203 **LPS models of acute lung injury replicate gene expression in hyperinflammatory ARDS**

204 Upstream regulator analysis identified LPS, a component of Gram-negative bacteria, as
205 a candidate upstream regulator of genes differentially expressed between ARDS phenotypes
206 (Supplementary Data 2A). LPS was also identified as an upstream regulator of gene expression
207 in comparisons of each ARDS phenotype to controls (Supplementary Data 2B, Supplementary
208 Data 2C). LPS is a potent stimulator of NF- κ B signaling via TLR4 and MyD88²⁵ and is frequently
209 used in experimental models of acute lung injury (ALI)²⁶ thus, we hypothesized that genes
210 upregulated in experimental models of lung injury would be enriched in genes that were
211 upregulated in hyperinflammatory ARDS compared to controls but would be relatively less
212 enriched in genes upregulated in hypoinflammatory ARDS compared to controls. Respiratory
213 tract gene expression data was available from four LPS models of ARDS in the Gene
214 Expression Omnibus. We also identified 17 more datasets from other experimental models of
215 ARDS including ventilator-induced lung injury (VILI), ozone, hyperoxia, Pam3Cys (a TLR2
216 agonist), and hemorrhagic shock (Supplementary Data 3A). We used GEO2Enrich²⁷ to identify
217 gene sets that were differentially expressed in lung injury compared to controls in experimental
218 models. We then used *gsva* to calculate a expression score for each of these gene sets in TA
219 samples and used *limma* to compare expression of these gene sets in each ARDS phenotype to
220 controls (Figure 1D, Supplementary Data 3B and 3C). Gene sets from four models were
221 significantly enriched (FDR < 0.1) in TA from both ARDS phenotypes. As expected, LPS models
222 had a significant overlap with both phenotypes, but LPS experimental gene sets had higher
223 GSVA scores in hyperinflammatory participants. In addition, gene sets from five experimental
224 models (two ozone models, two LPS models, and one VILI model) were enriched in
225 hyperinflammatory ARDS, but were not enriched in hypoinflammatory ARDS, suggesting these
226 models better replicate dysregulated gene expression observed in the hyperinflammatory
227 phenotype.

228

229

230 **Transcriptomes identify candidate drugs for hyperinflammatory ARDS**

231 To identify candidate treatments for each ARDS phenotype, we next used IPA's
232 Upstream Regulator Analysis to identify drugs that were predicted to shift gene expression from
233 each ARDS phenotype toward control subjects. This approach has been used to identify drugs
234 that can be tested in experimental models and clinical systems, and we have previously used
235 this approach to identify candidate treatments for COVID-19 ARDS.^{16,28} This *in silico* analysis
236 identified several drugs predicted to shift gene expression in the hyperinflammatory phenotype
237 toward ventilated controls (Figure 1.E.i, Supplementary Data 2B), while fewer drugs were
238 predicted to shift gene expression in hypoinflammatory ARDS toward controls (Figure 1.E.ii,
239 Supplementary Data 2C). Interestingly, our analysis also identified drugs predicted to shift gene
240 expression from control mechanically ventilated patients toward ARDS phenotypes. For
241 example, nitrofurantoin, amiodarone, and cytarabine, all of which cause drug-induced
242 pneumonitis, were predicted to shift gene expression from controls toward the
243 hyperinflammatory phenotype (Figure 1.E.ii).

244

245 **TA immune cells are distinctly polarized in hyperinflammatory ARDS**

246 To identify the sources of differential gene expression identified in bulk RNA sequencing
247 data, we used a neutrophil-preserving single-cell RNA sequencing (scSeq) pipeline to study TA
248 from eight COVID-negative patients with ARDS enrolled in a separate prospective,
249 observational cohort, the COVID-19 Multiphenotyping for Effective Therapies (COMET) study.
250 TA scSeq was available from six participants with hypoinflammatory ARDS and two participants
251 with hyperinflammatory ARDS. 18,717 cells passed quality control filters (3,782 from
252 hyperinflammatory ARDS, Figure 2A). We determined cell identities using SingleR²⁹ to compare
253 cell transcriptomes to signatures derived from the Human Primary Cell Atlas (Figure 2B).
254 Neutrophils were the most common cell type identified in TA from both phenotypes (48% of
255 hyperinflammatory TA cells and 36% of hypoinflammatory TA cells, Figure 2C), which
256 highlighted the importance of using neutrophil-preserving methods to study ARDS phenotypes.

257 To identify cell-specific differences between ARDS phenotypes, we used *MAST* to fit
258 mixed effects models of differential gene expression ($FDR < 0.1$)³⁰. To address
259 pseudoreplication bias and account for within-subject correlation in gene expression³¹, we
260 modeled ARDS phenotype as a fixed effect and each subject as a random effect. 231 genes
261 were differentially expressed between phenotypes in TA neutrophils (Figure 2.D.i,
262 Supplementary Data 4A). CCL2/MCP-1, which synergistically promotes neutrophil migration
263 with IL-8 and is elevated in bronchoalveolar lavage (BAL) fluid from LPS-challenged volunteers

264 and patients with ARDS³², was identified as an upstream regulator of neutrophil gene
265 expression in hyperinflammatory ARDS (Figure 2.D.ii, Supplementary Data 5A). In addition,
266 upstream regulator analysis predicted increased activation of MYC, a key mediator of
267 granulopoiesis³³, and MLXIPL, which promotes glycolysis³⁴, in hyperinflammatory neutrophils
268 (Figure 2.D.iii, Supplementary Data 5A). Notably, increased glycolytic activity has previously
269 been reported in LPS-stimulated neutrophils³⁵. In contrast to our bulk RNASeq analysis,
270 upstream regulator analysis predicted relatively higher activation of several proinflammatory
271 cytokines, including TNF, IL6, and IFNG, in hypoinflammatory neutrophils.

272 Next, we investigated differences in monocytes and macrophages in ARDS phenotypes.
273 189 genes were differentially expressed between 690 hyperinflammatory monocytes and
274 3802 hypoinflammatory monocytes (Figure 2.E.i, Supplementary Data 4B) while 339 genes
275 were differentially expressed in 296 monocyte-derived macrophages (MDM) from
276 hyperinflammatory ARDS and 1,930 MDM from hypoinflammatory ARDS (Figure 2.F.i,
277 Supplementary Data 4C). Only 15 genes were differentially expressed in alveolar macrophages
278 (Supplementary Data 4D), which was insufficient for pathway analysis and suggested these
279 cells played less of a role in differences between ARDS phenotypes. As in the neutrophils, IPA
280 predicted relatively higher activation of several pro-inflammatory cytokines in hypoinflammatory
281 ARDS, including TNF, IL1B, and IFNG, in monocytes and MDM, while two canonical Type 2
282 cytokines, IL4 and IL13, were predicted to be activated in hyperinflammatory ARDS for both cell
283 types (Figure 2.E.ii and 2.F.ii, Supplementary Data 5B and 5C). As in the bulk RNASeq data, we
284 observed higher activation of NFE2L2, which protects against oxidative stress and inhibits the
285 NLRP3 inflammasome³⁷ in monocytes and MDM from hyperinflammatory ARDS (Figure 2.E.iii
286 and Figure 2.F.iii).

287 We next compared gene expression in T cells and found 281 genes that were
288 differentially expressed between 477 T cells from hyperinflammatory ARDS and 1,665 T cells
289 from hypoinflammatory ARDS (Figure 2.G.i, Supplementary Data 4E). IPA identified activation
290 expression of interferon, TLR4, and NF-KB stimulated genes in T cells from the
291 hyperinflammatory phenotype (Figure 2.G.ii, Supplementary Data 5D), which was consistent
292 with the pattern observed in bulk RNA sequencing and suggested these T cells were T_h1
293 polarized. IPA also predicted increased activation of cell differentiation markers (NONO) and
294 activation of the integrated stress response (XBP1, EIF2AK2) in T cells from the
295 hyperinflammatory phenotype (Figure 2.G.iii, Supplementary Data 5D).

296 We used *connectome*³⁸, which compares single-cell gene expression to the FANTOM5
297 ligand-receptor database³⁹, to identify ligand-receptor pairs in lower respiratory cells that were

298 unique to each ARDS phenotype (Supplementary Data 6A and 6B). Several ligand-receptor
299 pairs were observed in hyperinflammatory ARDS but were not present in hypoinflammatory
300 ARDS (Supplementary Figure 3). For example, *IFNG* from T and NK cells and *IFNGR2* on MDM
301 were identified as a distinct ligand-receptor pair in hyperinflammatory ARDS, suggesting these
302 cells play a key role in the dysregulated pathways identified in bulk and single-cell differential
303 expression analyses. Together, our scSeq analyses confirm that TA immune cells have distinct
304 transcriptomic profiles in each ARDS phenotype.

305

306 **Plasma proteomic analysis identifies additional cytokines that are upregulated in** 307 **hyperinflammatory ARDS**

308 To further validate the biologic relevance of the TA findings, we used the O-Link Target
309 96 Inflammation panel to measure plasma protein biomarker concentrations. 21 participants
310 included in the TA bulk sequencing analysis also had plasma O-link data available. In addition,
311 proteomic data was available for four participants from the same cohort who did not have TA
312 bulk sequencing available for analysis. Of the 25 included participants, five had
313 hyperinflammatory ARDS and 20 had hypoinflammatory ARDS. We also measured plasma
314 protein concentrations in 14 healthy volunteers on the same O-link plate.

315 Plasma concentrations of 28 proteins were higher in hyperinflammatory ARDS than in
316 hypoinflammatory ARDS (FDR < 0.1, Figure 3A). Some of these biomarkers confirmed known
317 differences between phenotypes, including higher concentrations of IL6 and TNF in
318 hyperinflammatory ARDS. In addition, we identified nine plasma protein biomarkers notably
319 higher in hyperinflammatory ARDS over controls (Figure 3B) but not higher in hypoinflammatory
320 ARDS compared to controls (Figure 3C), suggesting they identify distinctly dysregulated
321 pathways in the hyperinflammatory phenotype. These proteins included IL-8, which is one of the
322 cytokines that defines the hyperinflammatory phenotype; CASP-8, an effector of FAS
323 signaling⁴⁰; the interferon gamma (IFN γ) induced proteins CXCL9 and CXCL10⁴¹; plasma
324 urokinase (uPA); oncostatin M; and adenosine deaminase (ADA). In addition, CCL2/MCP-1 and
325 the T cell activation marker CD5⁴² were higher in hyperinflammatory ARDS and in controls
326 compared to hypoinflammatory ARDS. These observations were consistent with observed
327 differences in TA gene expression at both the bulk RNASeq and scSeq level, particularly
328 increased CCL2 and FAS activity, IFN γ -stimulated gene expression, and T cell activation in
329 hyperinflammatory ARDS.

330

331

332 **Phenotypes were associated with differences in the respiratory microbiome**

333 Because our analyses demonstrated significant differences in host respiratory tract
334 biology in each phenotype, we hypothesized that each phenotype would have a distinct
335 respiratory microbiome that could stimulate a dysregulated response. We used a previously
336 described metagenomic sequencing pipeline to align non-human sequences in TA sequencing
337 to microbial genomes⁴³ and used established methods to filter background contamination from
338 samples⁴⁴. Taxa were aggregated at the genus level for downstream analyses. There was no
339 significant difference in alpha diversity between phenotypes for all microbial taxa, bacteria, or
340 fungi (Figure 4A). There was a significant difference in microbial community composition
341 between phenotypes (Bray-Curtis distance, PERMANOVA $p = 0.001$, Figure 4B). This
342 difference was not significant when the analysis was restricted to bacterial taxa ($p = 0.117$,
343 Figure 4C), but was significant when the analysis was restricted to fungal taxa ($p = 0.004$,
344 Figure 4D). We next compared differential abundance of microbial transcripts using
345 *metagenomeSeq*⁴⁵. We found increased abundance of *Candida* in TA from patients with
346 hyperinflammatory ARDS (Figure 4E). In addition, we observed greater abundance of multiple
347 bacterial taxa in the hypoinflammatory phenotype, including *Escherichia*, *Proteus*, and
348 *Citrobacter*, three taxa in the *Enterobacteriaceae* family, which was associated with an increased
349 risk of ARDS in a cohort of trauma patients⁴⁶. Together, these observations support the
350 hypothesis that there is a significant difference in microbial community composition between
351 ARDS phenotypes.

352

353 **Discussion**

354 In this study, we performed an integrated transcriptomic and proteomic analysis of
355 ARDS phenotypes. To our knowledge, this represents the first demonstration of differences in
356 pulmonary biology between molecular phenotypes of ARDS, which have previously been
357 characterized primarily using plasma biomarkers. We identified differences between phenotypes
358 in bulk RNA transcriptomes and used scSeq to identify distinctly polarized immune cells in the
359 TA. In addition, O-Link proteomics identified differences in plasma protein concentrations
360 consistent with these observations. We also found significant differences in the TA microbial
361 community composition between phenotypes. Our findings support the hypothesis that each
362 ARDS phenotype has distinct pulmonary pathobiology and may be more likely to respond to
363 treatments specifically targeting these dysregulated pathways.

364 Here, we find hyperinflammatory ARDS was associated with markedly higher IFN γ
365 stimulated gene expression and T cell activation in TA. In bulk RNA sequencing, pathway

366 analysis identified markedly higher expression of IFN γ stimulated genes and increased
367 expression of genes stimulated by the T cell receptor. Plasma proteomics identified increased
368 concentrations of the IFN γ -stimulated proteins CXCL9 and CXCL10 and the T cell activation
369 marker CD5 in hyperinflammatory ARDS but not in hypoinflammatory ARDS. Notably, in an
370 alternative molecular phenotyping approach that used *k*-means clustering of plasma biomarkers
371 to categorize ARDS subjects into two molecular phenotypes (“reactive” and “uninflamed”),
372 plasma IFN γ is one of the defining biomarkers of the higher mortality “reactive” phenotype⁴⁷.
373 Together, our analyses support a central role of IFN γ and T cell activation in hyperinflammatory
374 ARDS.

375 We used scSeq to identify cell-specific differences in immune responses. We found
376 evidence of increased neutrophil migration and differentiation in hyperinflammatory ARDS.
377 MDM from the higher-mortality hyperinflammatory phenotype expressed fewer pro-inflammatory
378 genes, which is consistent with a prior analysis showing decreased pro-inflammatory gene
379 expression in BAL macrophages collected on the day of intubation was associated with
380 increased mortality in a cohort of ARDS patients⁴⁸. In contrast, T cells demonstrated higher
381 interferon-stimulated gene expression in hyperinflammatory ARDS. Interestingly, this pattern of
382 high interferon-stimulated gene expression in T cells but diminished immune responses in
383 macrophages has also been reported in severe COVID-19⁴⁹. These findings suggest
384 dysregulated responses to immune signaling in specific cell populations may drive inflammation
385 in hyperinflammatory ARDS.

386 The interplay of the respiratory microbiome, lung injury, and ARDS has long been
387 hypothesized but remains an important knowledge gap in the field. In one experimental study,
388 changes in the respiratory microbiome mediated lung injury⁵⁰, however, a small prior study
389 using 16S sequencing of mini-BAL specimens found no difference in the microbiome
390 composition between phenotypes⁵¹. Because we used metatranscriptomic sequencing, we were
391 able to identify non-bacterial taxa present in TA samples. We identified significant differences in
392 microbial community composition between phenotypes and more transcripts from *Candida* in
393 hyperinflammatory ARDS. Decreased fungal diversity in the respiratory tract has previously
394 been associated with increased organ dysfunction and shock in patients with ARDS⁵², and an
395 increased burden of BAL *Candida* is associated with worse outcomes in ventilated patients with
396 COVID⁵³. Prior studies have also shown an association between *Enterobacteriaceae* and a risk
397 of developing ARDS^{46,54}; in our analysis, three genera in *Enterobacteriaceae* (*Escherichia*,
398 *Proteus*, and *Citrobacter*) were more abundant in hypoinflammatory ARDS than
399 hyperinflammatory ARDS. While *Candida* can stimulate the dysregulated pathways observed in

400 hyperinflammatory ARDS⁵⁵, further research is required to determine if the respiratory
401 microbiome causes (or, alternatively, results from) inflammation in hyperinflammatory ARDS,
402 and, if the association is causal, which taxa are responsible for lung injury.

403 We compared differentially expressed genes in clinical samples to experimental ALI
404 models. A prior analysis comparing rodent ALI models to human LPS challenge models found a
405 significant overlap in gene expression between animal and human experimental systems⁵⁶. An
406 experimental model combining intratracheal LPS *and* mechanical ventilation was the murine
407 model with the strongest overlap in gene expression with ARDS subjects in both phenotypes.
408 This gene signature was from an experiment demonstrating that a combined MV/LPS model
409 generated markedly higher neutrophilic inflammation in the lung than LPS or MV alone⁵⁷. These
410 observations suggest a two-hit model reproduces important biological changes observed in
411 ARDS. In addition, gene signatures from five models were enriched in hyperinflammatory ARDS
412 but were not enriched in hypoinflammatory ARDS, suggesting these models did not replicate
413 respiratory tract biology of the latter group. These observations may partially explain why
414 therapies that appear promising in pre-clinical models are not effective in more heterogeneous
415 clinical trial populations.

416 Our results provide further evidence that ARDS molecular phenotypes identify
417 biologically-important differences in immune biology, and have several important implications for
418 developing a precision approach to treating ARDS⁴. Pathway analyses identified different drugs
419 that were predicted to shift gene expression from ARDS toward ventilated controls in each
420 phenotype. These candidate therapies require further investigation in pre-clinical models, and
421 our results also demonstrate that some experimental models are more effective at reproducing
422 changes in gene expression observed in clinical samples in each phenotype. Future preclinical
423 studies and RCTs must account for this biological heterogeneity.

424 Strengths of this study include transcriptomic analysis of samples from the focal organ of
425 injury in ARDS, providing a highly detailed picture of the pulmonary biology of both ARDS
426 phenotypes, and validation of these observations with metatranscriptomics, single-cell
427 sequencing, and peripheral blood proteomics. In addition, the inclusion of non-ARDS ventilated
428 controls allowed us to further characterize the physiologic dysregulation in the phenotypes,
429 rather than defining gene expression relative to another pathologic state. This approach also
430 allowed us to compare our clinical samples to experimental models and identify candidate
431 medications that may be suitable for clinical trials in each phenotype.

432 This analysis also has some limitations. The sample size for each analysis is modest;
433 however, it was adequately powered to detect large changes in gene expression and protein

434 concentrations. We performed CD45⁺ selection for scSeq samples, which allowed us to isolate
435 hematopoietic immune cells, including neutrophils, but selected against epithelial cells, which
436 generate important signals in our bulk RNASeq and plasma protein analyses and likely play a
437 important role in ARDS phenotype biology. In addition, while TA contains fluid from the distal
438 airspaces⁵⁸, and we have previously shown that TA and BAL isolate similar immune cells¹⁶ and
439 microbiota⁵⁹, it is possible that more invasive BAL testing may identify additional differences
440 between the phenotypes. Future analyses should include larger cohorts to replicate these
441 findings and determine if TA sequencing or plasma cytokines more accurately predict clinical
442 trajectory and response to treatment.

443 In conclusion, an integrated, multi-omic analysis of ARDS molecular phenotypes defined
444 by plasma protein biomarkers suggests the hyperinflammatory phenotype is characterized by
445 marked differences in TA gene expression, metagenomics, and plasma proteins. Our findings
446 suggest the respiratory tract biology of these phenotypes is distinct and further supports the use
447 of molecular phenotypes to study acute lung injury biology and develop new treatments for
448 ARDS.

	Hyperinflammatory	Hypoinflammatory	P (1)	Control	P (2)	P (3)
N	10	31		5		
Age	66 [56, 72]	63 [51, 70]	0.63	66 ± 23	0.85	0.42
Female	4 (40)	21 (68)	0.95	3 (60)	0.26	0.49
BMI (kg/m²)	25.0 [23.6, 25.6]	25.9 [23.9, 32.2]	0.27	25.7 ± 4.8	0.24	0.23
Vasopressors at enrollment	9 (90)	19 (61)	0.19	1 (20)	<0.01	0.21
IL-8, pg/ml	424 [228, 1068]	15 [9, 25]	<0.01	10 [8, 11]	<0.01	0.21
Protein C, % control	51 [31, 62]	103 [76, 132]	<0.01	115 [79, 148]	<0.01	0.76
Immunosuppression	4 (40)	6 (19)	0.37			
Primary ALI Risk Factor			0.79			
<i>Pneumonia</i>	4 (40)	16 (48)				
<i>Sepsis</i>	4 (40)	7 (23)				
<i>Aspiration</i>	2 (20)	6 (23)				
<i>Pancreatitis</i>	0 (0)	1 (3)				
<i>None</i>	0 (0)	1 (3)				
Clinical microbiology*						
<i>Respiratory virus</i>	1 (10)	1 (3)	0.98			
<i>Respiratory bacteria</i>	3 (30)	11 (36)	1.00			
<i>Extrapulmonary bacteria</i>	3 (30)	5 (16)	0.62			
<i>Extrapulmonary fungus</i>	4 (40)	0 (0)	<0.01			

449 **Table 1:** Characteristics of patients included in differential expression analysis of ARDS phenotypes from the Acute Lung Injury in
450 Critical Illness cohort. Normally distributed values are reported as mean ± SD. Non-normally distributed values are reported as
451 median [IQR]. Categorical data are reported as N (% of total for category). P-values are for a t-test for normally distributed
452 continuous data, Wilcoxon rank-sum for non-normally distributed, and chi-square test for categorical data. P values are for (1)
453 hyperinflammatory ARDS vs. hypoinflammatory ARDS; (2) hyperinflammatory ARDS vs. controls; (3) hypoinflammatory ARDS vs.
454 controls. *No subjects in this cohort had a systemic viral infection or respiratory fungal infection.

455 Captions

456

457 **Figure 1:** Bulk RNA sequencing analyses of TA collected in the Acute Lung Injury in Critical
458 Illness cohort.

459

460 A-C) Differential gene expression and IPA upstream regulator scores in TA. A) 10
461 hyperinflammatory ARDS participants vs. 31 hypoinflammatory ARDS participants. B) 10
462 hyperinflammatory ARDS participants vs. five hypoinflammatory ARDS participants. C) 31
463 hypoinflammatory ARDS participants vs. five control participants.

464

465 For each comparison: (i) volcano plot of differential gene expression, where the \log_2 fold
466 difference is on the x-axis and the $-\log_{10}$ adjusted p-value is on the y-axis; (ii-iv) IPA upstream
467 regulator z-scores for (ii) cytokines, (iii) transmembrane and nuclear receptors, and (iv)
468 transcription regulators in the IPA database. A maximum of 20 significant upstream regulators
469 are shown for each panel. Redundant upstream regulators (e.g. inteferons or interleukins in the
470 same family) were omitted from the figure. For a complete list of upstream regulator scores, see
471 Supplementary Data 2.

472

473 D) Gene set variation analysis for experimental models of lung injury. We identified 21 models
474 of acute lung injury in the Gene Expression Omnibus and used GEO2Enrichr to identify up to
475 200 genes differentially expressed ($FDR < 0.05$) in the experimental model compared to
476 controls. GSVA scores were calculated for each sample, and the difference between
477 hyperinflammatory ARDS and controls (orange) and hypoinflammatory ARDS and controls
478 (blue) was estimated with limma. Experimental gene sets that are significantly different from
479 controls are shown with solid triangles, while gene sets that are not significant are shown with
480 transparent circles. For each model, the GEO Accession Number, organism, and lung injury
481 model are listed on the x-axis.

482

483 E) IPA Upstream Regulator Analysis scores for selected drugs in the IPA database for (i)
484 hyperinflammatory ARDS vs. controls, and (ii) hypoinflammatory ARDS vs. controls. A positive
485 z-score indicates the drug is predicted to shift gene expression from ventilated lungs toward
486 ARDS lungs, while a negative score indicates the drug is predicted to shift gene expression
487 from ARDS towards controls. Upstream regulators that did not meet statistical significance
488 criteria are displayed using a transparent dot.

489

490 **Figure 2:** Single-cell RNA sequencing from TA in the COMET cohort. A) Seurat UMAP
491 projection of 18,717 TA cell transcriptomes from two participants with hyperinflammatory ARDS
492 and six participants with hypoinflammatory ARDS, annotated with cell type as predicted by
493 SingleR. B) UMAP projection of TA cells transcriptomes separated by ARDS phenotype. C) Bar
494 plot of cell proportions in each phenotype.

495

496 D-G) Differential expression and pathway analyses for D) Neutrophils, E) Monocytes, F)
497 Monocyte-derived macrophages, and G) T cells. For each cell type: (i) volcano plot of
498 differential gene expression. A positive fold change indicates the gene is more highly expressed
499 in hyperinflammatory ARDS. (ii) IPA upstream regulator scores for cytokines and (iii) IPA
500 upstream regulator scores for the top 40 non-cytokine regulators of gene expression. A positive
501 z-score indicates the cytokine is predicted to be more active in hyperinflammatory ARDS
502 compared to hypoinflammatory ARDS.

503

504 **Figure 3:** O-Link proteomics results for plasma biomarkers from 5 hyperinflammatory ARDS, 20
505 hypoinflammatory ARDS, and 14 control participants. Each heatmap shows plasma protein

506 biomarkers that were significantly different between groups (FDR < 0.1); for a complete list of
507 proteins, see Supplementary Data 7. Each column represents an individual subject and each
508 row shows the z-scaled concentrations. Rows and columns are clustered using the Euclidean
509 distance. Columns are annotated by phenotype (orange is hyperinflammatory, blue is
510 hypoinflammatory, and green is healthy volunteer). Z-score for expression is shown on the color
511 bar on the right, and the scale is the same across all three heatmaps. A) Hyperinflammatory
512 ARDS vs. hypoinflammatory ARDS. B) Hyperinflammatory ARDS vs. healthy volunteers. C)
513 Hypoinflammatory ARDS vs. healthy volunteers.

514
515 **Figure 4:** Results of metatranscriptomic sequencing analyses of TA from 31 subjects with
516 hypoinflammatory ARDS and 10 subjects with hyperinflammatory ARDS from the Acute Lung
517 Injury in Critical Illness cohort. All analyses are performed with metatranscriptomic data
518 aggregated at the genus level. A) Shannon diversity index for each TA sample, shown for all
519 taxa, bacteria, and fungi. Each point represents an individual participant. P-value for Wilcoxon
520 rank-sum test. B-D) Principal components analysis of metatranscriptomic reads mapped to all
521 taxa, bacteria, or fungi in TA. Each point represents an individual subject. Subjects with
522 systemic fungal infections are identified with triangles. Ellipses show the 95% confidence
523 interval around the centroid. PERMANOVA for Bray-Curtis dissimilarity was calculated using
524 adonis2 in vegan. D) Volcano plot showing differential abundance for TA metatranscriptomes.
525 Genera that are significantly higher in hyperinflammatory ARDS are in orange and genera that
526 are significantly higher in hypoinflammatory ARDS are in blue.

527
528 **Supplementary data 1:** Differential gene expression for pairwise comparisons of bulk RNA
529 gene expression for TA in the Acute Lung Injury in Critical Illness cohort. A positive log₂ fold
530 difference indicates the gene is more highly expressed in the first group compared to second
531 group for each comparison. A) Hyperinflammatory ARDS vs. hypoinflammatory ARDS; B)
532 Hyperinflammatory ARDS vs. controls; and C) Hypoinflammatory ARDS vs. controls; and D) All
533 ARDS subjects vs. controls.

534
535 **Supplementary data 2:** IPA Upstream Regulator scores for pairwise comparisons of bulk RNA
536 gene expression for TA in the Acute Lung Injury in Critical Illness Cohort. A positive z-score
537 indicates gene expression is consistent with higher activity of the upstream regulator in the first
538 group compared to second group for each comparison. A) Hyperinflammatory ARDS vs.
539 hypoinflammatory ARDS; B) Hyperinflammatory ARDS vs. controls; C) Hypoinflammatory
540 ARDS vs. controls; and D) All ARDS vs. controls.

541
542 **Supplementary data 3:** A) 200 most upregulated genes in experimental models of lung injury
543 compared to controls for 21 experimental systems in the Gene Expression Omnibus. B) Gene
544 set enrichment analysis scores and leading edge genes for experimental model gene sets in TA
545 differential expression for hyperinflammatory ARDS vs. controls. C) Gene set enrichment
546 analysis scores and leading edge genes for experimental model gene sets in TA differential
547 expression for hypoinflammatory ARDS vs. controls.

548
549 **Supplementary data 4:** Differential gene expression for single-cell RNA sequencing for TA for
550 the COMET cohort. A positive log₂ fold difference indicates the gene is more highly expressed in
551 hyperinflammatory ARDS. A) Neutrophils, B) Monocytes, C) Monocyte-derived macrophages,
552 D) Alveolar macrophages, E) T cells, F) Dendritic cells

553
554 **Supplementary data 5:** IPA Upstream Regulator scores for pairwise comparisons of bulk RNA
555 gene expression for TA in the COMET. A positive z-score indicates gene expression is
556 consistent with higher activity of the upstream regulator in the hyperinflammatory ARDS

557 samples. A) Neutrophils, B) Monocytes, C) Monocyte-derived macrophages, D) T cells, and E)
558 Dendritic cells

559

560 **Supplementary Data 6:** Connectome results for ligand-receptor pairs in TA single-cell RNA
561 sequencing from the COMET cohort for A) hyperinflammatory ARDS and B) hypoinflammatory
562 ARDS.

563

564 **Supplementary Data 7:** A) Z-scaled O-link protein concentrations for five hyperinflammatory
565 ARDS, 20 hypoinflammatory ARDS, and 14 control subjects. B) Results of Wilcoxon rank-sum
566 tests for pairwise comparisons of hyperinflammatory ARDS, hypoinflammatory ARDS, and
567 control subjects.

568

569 **Supplementary figure 1:** Subjects included in this analysis.

570

571 **Supplementary figure 2:** Sensitivity analysis for differential gene expression between
572 phenotypes after adjusting for fungal infections. (A) volcano plot of differential gene expression,
573 where the \log_2 fold difference is on the x-axis and the $-\log_{10}$ adjusted p-value is on the y-axis.
574 (B) Scatter plot showing estimated \log_2 -fold difference in gene expression between phenotypes.
575 The \log_2 -fold difference in gene expression without adjusting for systemic fungal infections is on
576 the x-axis, and the \log_2 -fold difference in gene expression after adjusting is shown on the y-axis.
577 (C-E) IPA upstream regulator z-scores for (C) cytokines, (D) transmembrane and nuclear
578 receptors, and (E) transcription regulators in the IPA database. A maximum of 20 significant
579 upstream regulators are shown for each panel. Redundant upstream regulators (e.g. interferons
580 or interleukins in the same family) were omitted from the figure. For a complete list of upstream
581 regulator scores, see Supplementary Data 2B.

582

583 **Supplementary figure 3:** Circos plots showing ligand-receptor pairs that are only significant in
584 hyperinflammatory ARDS.

585

586 **Supplementary figure 4:** Heatmaps for plasma proteins that are significantly higher in A)
587 Controls vs. hyperinflammatory ARDS and B) Controls vs. hypoinflammatory ARDS

588 **References**

- 589 1. Matthay, M. A. *et al.* Acute respiratory distress syndrome. *Nature Reviews Disease Primers*
590 **5**, 1–22 (2019).
- 591 2. Abani, O. *et al.* Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a
592 randomised, controlled, open-label, platform trial. *The Lancet* **397**, 1637–1645 (2021).
- 593 3. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19.
594 *New England Journal of Medicine* **384**, 693–704 (2021).
- 595 4. Beitler, J. R. *et al.* Advancing precision medicine for acute respiratory distress syndrome.
596 *Lancet Respir Med* S2213-2600(21)00157–0 (2021) doi:10.1016/S2213-2600(21)00157-0.
- 597 5. Calfee, C. S. *et al.* Subphenotypes in acute respiratory distress syndrome: latent class
598 analysis of data from two randomised controlled trials. *The Lancet Respiratory Medicine* **2**,
599 611–620 (2014).
- 600 6. Famous, K. R. *et al.* Acute respiratory distress syndrome subphenotypes respond differently
601 to randomized fluid management strategy. *American Journal of Respiratory and Critical*
602 *Care Medicine* **195**, 331–338 (2017).
- 603 7. Calfee, C. S. *et al.* Acute respiratory distress syndrome subphenotypes and differential
604 response to simvastatin: secondary analysis of a randomised controlled trial. *The Lancet*
605 *Respiratory Medicine* **6**, 691–698 (2018).
- 606 8. Sinha, P. *et al.* Latent class analysis of ARDS subphenotypes: a secondary analysis of the
607 statins for acutely injured lungs from sepsis (SAILS) study. *Intensive Care Medicine* **44**,
608 1859–1869 (2018).

- 609 9. Sinha, P. *et al.* Latent class analysis-derived subphenotypes are generalisable to
610 observational cohorts of acute respiratory distress syndrome: a prospective study. *Thorax*
611 (2021) doi:10.1136/thoraxjnl-2021-217158.
- 612 10. Meyer, N. J., Gattinoni, L. & Calfee, C. S. Acute respiratory distress syndrome. *The Lancet*
613 **398**, 622–637 (2021).
- 614 11. Maddali, M. V. *et al.* Validation and utility of ARDS subphenotypes identified by machine-
615 learning models using clinical data: an observational, multicohort, retrospective analysis.
616 *The Lancet Respiratory Medicine* (2022) doi:10.1016/S2213-2600(21)00461-6.
- 617 12. Sinha, P. *et al.* Latent Class Analysis Reveals COVID-19–related Acute Respiratory Distress
618 Syndrome Subgroups with Differential Responses to Corticosteroids. *Am J Respir Crit Care*
619 *Med* **204**, 1274–1285 (2021).
- 620 13. Chen, H. *et al.* Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill
621 Patients With COVID-19 With Hyperinflammatory Phenotype. *Chest* **159**, 1793–1802 (2021).
- 622 14. Sinha, P. *et al.* Development and validation of parsimonious algorithms to classify acute
623 respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled
624 trials. *Lancet Respir Med* **8**, 247–257 (2020).
- 625 15. Sinha, P., Churpek, M. M. & Calfee, C. S. Machine Learning Classifier Models Can Identify
626 Acute Respiratory Distress Syndrome Phenotypes Using Readily Available Clinical Data. *Am J*
627 *Respir Crit Care Med* **202**, 996–1004 (2020).
- 628 16. Sarma, A. *et al.* Tracheal aspirate RNA sequencing identifies distinct immunological features
629 of COVID-19 ARDS. *Nat Commun* **12**, 5152 (2021).

- 630 17. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for
631 RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 632 18. Zhu, A., Ibrahim, J. G. & Love, M. I. Heavy-tailed prior distributions for sequence count data:
633 removing the noise and preserving large differences. *Bioinformatics* **35**, 2084–2092 (2019).
- 634 19. Krämer, A., Green, J., Pollard, J. & Tugendreich, S. Causal analysis approaches in Ingenuity
635 Pathway Analysis. *Bioinformatics* **30**, 523–530 (2014).
- 636 20. Waldmann, T. A. The biology of interleukin-2 and interleukin-15: implications for cancer
637 therapy and vaccine design. *Nat Rev Immunol* **6**, 595–601 (2006).
- 638 21. Wolf, L. *et al.* IL-17A-mediated expression of epithelial IL-17C promotes inflammation
639 during acute *Pseudomonas aeruginosa* pneumonia. *American Journal of Physiology-Lung
640 Cellular and Molecular Physiology* **311**, L1015–L1022 (2016).
- 641 22. Caulfield, A. J. & Lathem, W. W. Disruption of Fas-Fas Ligand Signaling, Apoptosis, and
642 Innate Immunity by Bacterial Pathogens. *PLOS Pathogens* **10**, e1004252 (2014).
- 643 23. Deguine, J. & Barton, G. M. MyD88: a central player in innate immune signaling.
644 *F1000Prime Rep* **6**, 97 (2014).
- 645 24. Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T. & Seya, T. TICAM-1, an adaptor
646 molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. *Nat
647 Immunol* **4**, 161–167 (2003).
- 648 25. Sakai, J. *et al.* Lipopolysaccharide-induced NF- κ B nuclear translocation is primarily
649 dependent on MyD88, but TNF α expression requires TRIF and MyD88. *Sci Rep* **7**, 1428
650 (2017).

- 651 26. Matute-Bello, G., Frevert, C. W. & Martin, T. R. Animal models of acute lung injury. *Am J*
652 *Physiol Lung Cell Mol Physiol* **295**, L379–L399 (2008).
- 653 27. Gundersen, G. W. *et al.* GEO2Enrichr: browser extension and server app to extract gene sets
654 from GEO and analyze them for biological functions. *Bioinformatics* **31**, 3060–3062 (2015).
- 655 28. Felciano, R. M. *et al.* Predictive systems biology approach to broad-spectrum, host-directed
656 drug target discovery in infectious diseases. *Pac Symp Biocomput* 17–28 (2013).
- 657 29. Aran, D. *et al.* Reference-based analysis of lung single-cell sequencing reveals a transitional
658 profibrotic macrophage. *Nat Immunol* **20**, 163–172 (2019).
- 659 30. Finak, G. *et al.* MAST: a flexible statistical framework for assessing transcriptional changes
660 and characterizing heterogeneity in single-cell RNA sequencing data. *Genome Biology* **16**,
661 278 (2015).
- 662 31. Zimmerman, K. D., Espeland, M. A. & Langefeld, C. D. A practical solution to
663 pseudoreplication bias in single-cell studies. *Nat Commun* **12**, 738 (2021).
- 664 32. Williams, A. E. *et al.* Evidence for chemokine synergy during neutrophil migration in ARDS.
665 *Thorax* **72**, 66–73 (2017).
- 666 33. Klimenkova, O. *et al.* A lack of secretory leukocyte protease inhibitor (SLPI) causes defects in
667 granulocytic differentiation. *Blood* **123**, 1239–1249 (2014).
- 668 34. Iizuka, K. The transcription factor carbohydrate-response element-binding protein
669 (ChREBP): A possible link between metabolic disease and cancer. *Biochimica et Biophysica*
670 *Acta (BBA) - Molecular Basis of Disease* **1863**, 474–485 (2017).
- 671 35. Sadiku, P. *et al.* Neutrophils Fuel Effective Immune Responses through Gluconeogenesis and
672 Glycogenesis. *Cell Metabolism* **33**, 411–423.e4 (2021).

- 673 36. Lawrence, T. & Natoli, G. Transcriptional regulation of macrophage polarization: enabling
674 diversity with identity. *Nat Rev Immunol* **11**, 750–761 (2011).
- 675 37. Zhao, C., Gillette, D. D., Li, X., Zhang, Z. & Wen, H. Nuclear factor E2-related factor-2 (Nrf2)
676 is required for NLRP3 and AIM2 inflammasome activation. *J Biol Chem* **289**, 17020–17029
677 (2014).
- 678 38. Raredon, M. S. B. *et al.* *Connectome: computation and visualization of cell-cell signaling*
679 *topologies in single-cell systems data*. 2021.01.21.427529
680 <https://www.biorxiv.org/content/10.1101/2021.01.21.427529v1> (2021)
681 doi:10.1101/2021.01.21.427529.
- 682 39. A draft network of ligand–receptor-mediated multicellular signalling in human | Nature
683 Communications. <https://www.nature.com/articles/ncomms8866>.
- 684 40. Muzio, M. *et al.* FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to
685 the CD95 (Fas/APO-1) Death-Inducing Signaling Complex. *Cell* **85**, 817–827 (1996).
- 686 41. Tannenbaum, C. S. *et al.* The CXC chemokines IP-10 and Mig are necessary for IL-12-
687 mediated regression of the mouse RENCA tumor. *J Immunol* **161**, 927–932 (1998).
- 688 42. Azzam, H. S. *et al.* CD5 Expression Is Developmentally Regulated By T Cell Receptor (TCR)
689 Signals and TCR Avidity. *Journal of Experimental Medicine* **188**, 2301–2311 (1998).
- 690 43. Kalantar, K. L. *et al.* IDseq—An open source cloud-based pipeline and analysis service for
691 metagenomic pathogen detection and monitoring. *GigaScience* **9**, giaa111 (2020).
- 692 44. Mick, E. *et al.* Upper airway gene expression reveals suppressed immune responses to
693 SARS-CoV-2 compared with other respiratory viruses. *Nat Commun* **11**, 5854 (2020).

- 694 45. Paulson, J. N., Stine, O. C., Bravo, H. C. & Pop, M. Differential abundance analysis for
695 microbial marker-gene surveys. *Nat Methods* **10**, 1200–1202 (2013).
- 696 46. Panzer, A. R. *et al.* Lung Microbiota Is Related to Smoking Status and to Development of
697 Acute Respiratory Distress Syndrome in Critically Ill Trauma Patients. *Am J Respir Crit Care*
698 *Med* **197**, 621–631 (2018).
- 699 47. Bos, L. D. *et al.* Identification and validation of distinct biological phenotypes in patients
700 with acute respiratory distress syndrome by cluster analysis. *Thorax* **72**, 876–883 (2017).
- 701 48. Morrell, E. D. *et al.* Alveolar Macrophage Transcriptional Programs Are Associated with
702 Outcomes in Acute Respiratory Distress Syndrome. *Am J Respir Crit Care Med* **200**, 732–741
703 (2019).
- 704 49. Yao, C. *et al.* Cell-Type-Specific Immune Dysregulation in Severely Ill COVID-19 Patients. *Cell*
705 *Reports* **34**, 108590 (2021).
- 706 50. Ashley, S. L. *et al.* Lung and gut microbiota are altered by hyperoxia and contribute to
707 oxygen-induced lung injury in mice. *Sci Transl Med* **12**, (2020).
- 708 51. Heijnen, N. F. L. *et al.* Biological subphenotypes of acute respiratory distress syndrome may
709 not reflect differences in alveolar inflammation. *Physiological Reports* **9**, e14693 (2021).
- 710 52. Britton, N. *et al.* Diversity of the lung mycobiome is associated with severity of disease in
711 acute respiratory distress syndrome. *European Respiratory Journal* **56**, (2020).
- 712 53. Sulaiman, I. *et al.* Microbial signatures in the lower airways of mechanically ventilated
713 COVID-19 patients associated with poor clinical outcome. *Nat Microbiol* **6**, 1245–1258
714 (2021).

- 715 54. Dickson, R. P. *et al.* Enrichment of the lung microbiome with gut bacteria in sepsis and the
716 acute respiratory distress syndrome. *Nat Microbiol* **1**, 16113 (2016).
- 717 55. Camilli, G., Griffiths, J. S., Ho, J., Richardson, J. P. & Naglik, J. R. Some like it hot: Candida
718 activation of inflammasomes. *PLOS Pathogens* **16**, e1008975 (2020).
- 719 56. Sweeney, T. E., Lofgren, S., Khatri, P. & Rogers, A. J. Gene Expression Analysis to Assess the
720 Relevance of Rodent Models to Human Lung Injury. *Am J Respir Cell Mol Biol* **57**, 184–192
721 (2017).
- 722 57. Altemeier, W. A. *et al.* Modulation of Lipopolysaccharide-Induced Gene Transcription and
723 Promotion of Lung Injury by Mechanical Ventilation. *The Journal of Immunology* **175**, 3369–
724 3376 (2005).
- 725 58. Bernhard, W. *et al.* Conductive airway surfactant: surface-tension function, biochemical
726 composition, and possible alveolar origin. *Am J Respir Cell Mol Biol* **17**, 41–50 (1997).
- 727 59. Kalantar, K. L. *et al.* Metagenomic comparison of tracheal aspirate and mini-bronchial
728 alveolar lavage for assessment of respiratory microbiota. *American Journal of Physiology-
729 Lung Cellular and Molecular Physiology* **316**, L578–L584 (2019).
- 730 60. Langelier, C. *et al.* Integrating host response and unbiased microbe detection for lower
731 respiratory tract infection diagnosis in critically ill adults. *Proceedings of the National
732 Academy of Sciences* **115**, E12353–E12362 (2018).
- 733 61. ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition.
734 *JAMA* **307**, 2526–2533 (2012).

- 735 62. Horan, T. C., Andrus, M. & Dudeck, M. A. CDC/NHSN surveillance definition of health care–
736 associated infection and criteria for specific types of infections in the acute care setting.
737 *American Journal of Infection Control* **36**, 309–332 (2008).
- 738 63. Tsitsiklis, A. *et al.* Impaired immune signaling and changes in the lung microbiome precede
739 secondary bacterial pneumonia in COVID-19. *Res Sq* (2021) doi:10.21203/rs.3.rs-380803/v1.
- 740 64. Chamberlain, S. A. & Szöcs, E. taxize: taxonomic search and retrieval in R. (2013)
741 doi:10.12688/f1000research.2-191.v2.
- 742 65. McMurdie, P. J. & Holmes, S. phyloseq: an R package for reproducible interactive analysis
743 and graphics of microbiome census data. *PLoS One* **8**, e61217 (2013).
- 744 66. Oksanen, J. *et al.* *vegan: Community Ecology Package*. (2020).
- 745

746 **Methods**

747 *Patient selection*

748 Subjects were selected from two prospective observational cohorts of critically ill
749 patients. The first, the Acute Lung Injury in Critical Illness study, is a cohort of mechanically
750 ventilated adults (age ≥ 18) admitted to the intensive care unit at the University of California,
751 San Francisco Medical Center (UCSFMC) between from July 2013 until March 2020, when
752 enrollment was paused due to the COVID-19 pandemic. The second, the COVID-19
753 Multiphenotyping for Effective Therapies (COMET) study, is a multi-omic study of hospitalized
754 patients with COVID-19 and hospitalized controls admitted to UCSFMC or Zuckerberg San
755 Francisco General Hospital (ZSFGH).

756 These studies were approved by the UCSF Institutional Review Board (17-24056, 20-
757 30497), which granted an initial waiver of informed consent to collect TA and blood samples
758 within 48 hours of ICU admission. Informed consent was then obtained from patients or
759 surrogates, as previously described⁶⁰.

760 In this analysis, we included all available subjects in each cohort who were: 1) admitted
761 to the intensive care unit for mechanical ventilation for ARDS or airway protection without
762 radiographic evidence of underlying pulmonary disease and 2) for whom we had TA sequencing
763 with at least 500,000 protein-coding counts. We reviewed PCA plots, hierarchical clustering, and
764 percentage of non-zero reads per samples for quality control and excluded four samples as
765 technical outliers. For our non-ARDS control patients, we excluded control subjects on
766 immunosuppression, including corticosteroids, and those with immunocompromising conditions
767 (HIV, chemotherapy, etc.).

768
769 *ARDS adjudication and phenotype assignment*

770 Subject charts were reviewed for ARDS adjudication by at least two study authors (AS,
771 PS, ES, FM, CL, ZL, KK, CH, MM, CC) blinded to all biological data. ARDS was diagnosed
772 using the Berlin Definition⁶¹. Lower respiratory tract infections were diagnosed using the CDC
773 surveillance definition⁶². ARDS phenotype was determined using a three-variable classifier
774 model (IL-8, protein C, and bicarbonate) previously developed and validated for this purpose¹⁴.
775 This classifier model assigns subjects a probability of assignment to the hyperinflammatory
776 molecular phenotype identified using latent class analyses. Subjects with a probability of class
777 assignment greater than 0.5 were assigned to the hyperinflammatory class. Plasma biomarkers
778 were not available for five subjects with TA bulk RNA sequencing. For these subjects, we used
779 a validated clinical classifier model to assign phenotype.^{11,15}

780
781 *RNA sequencing*

782 Following enrollment, TA was collected and stored in RNase free conditions as
783 previously described⁶⁰. Metagenomic next generation sequencing (mNGS) of RNA was
784 performed on TA specimens using an established sequencing pipeline. Following RNA
785 extraction (Zymo Pathogen Magbead Kit) and DNase treatment, human cytosolic and
786 mitochondrial ribosomal RNA was depleted using FastSelect (Qiagen). To control for
787 background contamination, we included negative controls (water and HeLa cell RNA) as well as
788 positive controls (spike-in RNA standards from the External RNA Controls Consortium (ERCC)).
789 RNA was then fragmented and underwent library preparation using the NEBNext Ultra II
790 RNASeq Kit (New England Biolabs). Libraries underwent 146 nucleotide paired-end Illumina
791 sequencing on an Illumina Novaseq 6000 instrument.

792

793 *Host differential expression and pathway analysis*

794 Following demultiplexing, sequencing reads were pseudo-aligned with *kallisto* (v. 0.46.1;
795 including bias correction) to an index consisting of all transcripts associated with human protein
796 coding genes (ENSEMBL v. 99), cytosolic and mitochondrial ribosomal RNA sequences, and
797 the sequences of ERCC RNA standards. Gene-level counts were generated from the transcript-
798 level abundance estimates using the R package *tximport*, with the scaledTPM method. Samples
799 retained in the dataset had a total of at least 500,000 estimated counts associated with
800 transcripts of protein coding genes, and the median across all samples was 7,528,890 counts.

801 We used an established bioinformatics pipeline to compare differential gene expression
802 in TA from hyperinflammatory and hypoinflammatory ARDS. Differential expression analysis
803 was performed using DESeq2. Gene expression was fit to a model using the design formula
804 ~Sequencing Batch + Gender + Z-scaled Age + Diagnosis. We performed pairwise comparisons
805 of 1) hyperinflammatory ARDS to hypoinflammatory ARDS, 2) all ARDS subjects to
806 mechanically ventilated controls, 3) hyperinflammatory ARDS to controls, and 4)
807 hypoinflammatory ARDS to controls. Empirical Bayesian shrinkage estimators for log₂-fold
808 change were fit using *apecglm*. Differentially expressed genes with an independent-hypothesis
809 weighted FDR < 0.1 and absolute shrunken log₂FoldChange greater than 0.5.

810 Differentially expressed genes were analyzed using Ingenuity Pathway Analysis (IPA,
811 Qiagen). We ran IPA Core Analyses for each pairwise comparison of differential gene
812 expression. IPA compares differentially expressed genes to a database of gene signatures
813 derived from experimental datasets. In addition to identifying signatures of canonical pathways
814 and cellular function, IPA includes a database of upstream regulators of gene function. These
815 include endogenous signaling molecules, such as cytokines, and exogenous stimuli, such as
816 drugs or toxins. The dataset also includes annotations of the relationship between regulators,
817 which can be used to construct mechanistic networks of regulators that may indirectly affect
818 gene expression. For each of the signatures, IPA calculates a p-value for the overlap of DE
819 genes with genes in the signature (using Fisher's exact test) and a z-score that tests whether
820 the measured direction of gene expression is consistent the direction in a gene signature. We
821 defined significant pathways, regulators, and networks as those with a Benjamini-Hochberg
822 false detection rate less than 0.1 or an absolute z-score greater than 2.

823
824 *Single-cell RNA sequencing*

825 TA were collected and stored at room temperature (to preserve neutrophils) and
826 processed within three hours as previously described⁶³. Briefly, TA cells were isolated and
827 selected for expression of CD45, prepared with a V(D)J v1.1 kit according to the manufacturer's
828 protocol, processed on a 10x Genomics Chip A without multiplexing, and sequenced on an
829 Illumina NovaSeq 6000 platform. Because samples had to be processed shortly after collection,
830 batch processing and multiplexing were not feasible. Transcripts were aligned in Cell Ranger
831 and filtered count matrices were imported into a Seurat object. Cells were filtered to have at
832 least 300 counts, no more than 30,000 counts, and less than 10% mitochondrial genes. Cell
833 types were determined using SingleR, and the Human Primary Cell Atlas was used as the
834 annotation reference. Patients were assigned phenotypes on the basis of plasma IL-8, protein
835 C, and bicarbonate concentrations. Differential gene expression for each cell type was
836 determined using *MAST*, using a mixed effects model with fixed effects for phenotype and
837 cellular detection rate and a random effect for subject. Differentially expressed genes were
838 identified using Benjamini-Hochberg FDR < 0.1.

839
840 *Plasma proteomic analysis*

841 Plasma samples were analyzed using the O-link Proteomics Assay. This assay
842 generates a semi-quantitative measure of plasma protein concentrations for 96 plasma
843 biomarkers. We excluded all samples that were flagged with a QC warning from the O-link

844 platform, and excluded any biomarker where protein concentrations could not be measured for
845 at least 90% of samples. Measurements for 73 of the biomarkers on the panel passed the
846 manufacturer's quality control filter and were included for analysis. Normalized protein
847 expression measurements were compared using a Wilcoxon rank-sum test and p-values were
848 adjusted using the Benajmini-Hochberg method (FDR < 0.1).
849













850 *Comparison of differentially expressed genes to experimental models of acute lung injury*

851 We selected experimental models of acute lung injury in the Gene Expression Omnibus
852 from a list of previously identified rodent and human models⁵⁶. Lists of all genes differentially
853 expressed at a Benjamini-Hochberg corrected p-value less than 0.05 were downloaded using
854 GEO2Enrich²⁷. We then used the genes that were upregulated in the experimental lung injury
855 model as gene signatures in GSVA. If more than 200 genes were differentially expressed in the
856 experimental model, we used the top 200 genes (by p-value) for the experimental gene
857 signature. A complete list of GEO accession numbers, experimental models, and genes used in
858 each signature can be found in Supplemental Table 3A. We used limma to compare GSVA
859 scores in samples from each phenotype to GSVA scores in controls.
860




861 *Metagenomic sequencing*




862 FASTQ files were analyzed using IDSeq⁴³ to identify microbial reads in TA
863 transcriptomes. Count matrices were downloaded for tracheal samples and water controls for
864 analysis in RStudio. Taxonomic data were downloaded from NCBI using taxize⁶⁴, and the matrix
865 was filtered to only include viruses, bacteria, and fungi. We fit a negative binomial model of
866 taxon-specific transcript counts against the total number of ERCC spike-in transcript reads in
867 each of the water control samples. We then used this model to predict the background
868 contamination of each taxon in each TA sample based on the number of ERCC reads. We then
869 subtracted the predicted contamination from the measured reads in the sample to estimate the
870 abundance in TA and rounded the estimate to the nearest integer. If the taxon-specific reads in
871 a TA sample were not significantly different from predicted background contamination after
872 adjusting for multiple comparisons using the Benjamini-Hochberg method, we estimated the
873 abundance as zero. This background-corrected count matrix was used to construct a phyloseq⁶⁵
874 object. Taxa were agglomerated at the genus level for downstream analysis.





875 We used estimate_richness to calculate the Shannon diversity index for all microbial
876 taxa, as well as subgroup analyses of bacterial and fungal genera, in TA samples. We then
877 used vegan⁶⁶ to estimate the Bray-Curtis dissimilarity between samples and used adonis2 to
878 calculate PERMANOVA p-values. We then used metagenomeSeq⁴⁵ to estimate differential
879 abundance between phenotypes using zero-inflated log-normal mixture models for each genus.
880 Normalization factors were calculated using Wrench normalization and differential abundance
881 was estimated using fitFeatureModel.
882

(A.i) Hyperinflammatory vs. Hypoinflammatory**(A.ii)****(A.iii)****(A.iv)****(B.i)****(B.ii)****(B.iii)****(B.iv)****(C.i)****(C.ii)****(C.iii)****(C.iv)**

Phenotype
 ● Control
 ● HypoARDS
 ● HyperARDS

(D)**(E.i)****(E.ii)**

A**B****C**

(A)**(B)****(C)****(D)****(E)**